Table 1 Effectiveness comparison for various histologies by anatomical location between Standard of Care (SOC) and Carbon Ions

Intracranial

  Glioma

2

< 20%

-

Location dependent

-

Trials ongoing^§†

  Meningioma

2

80-90%

-

Location dependent

-

Trials ongoing^§‡

Head and Neck

  Adenoid cystic

3

27-72%

26-96%

0-12.9%

0-17%

[141, 142]

  Bone/soft tissue sarcoma

2

43-70%

24-73%

0%

2-18.5%

[20, 140, 143–147]

  Skull base

3

46-73%

82-88%

0-7%

0-5%

[117–121, 148]

Thorax

  NSCLC

4

80-97%

90-95%

0-15%

3% (pneumonitis)

[21, 149]

Abdomen and Pelvis

  HCC

4

75-96%

81-96%

7-22%

3-4%

[21, 130–133, 150]

  Pancreas

2

10-20%

66-100%

1.8-20%

7.7%

[136, 151–153]

  Prostate

2

80-95%**

87-99%*

4-28%

0.1-25%

[21, 24, 154–159]

  Rectal cancer

1

24-28%

95%

14-27%

-

[21, 160–162]

  Cervix cancer

1

20%

53%

0-10.6

9.6-18.2%

[163–165]

  Sacral chordoma

1

55-72%

88%

17.6%

5.9%-17.9%

[166–168]

  Chondrosarcoma

1

20-40%

60%

-

-

[167, 168]